Abstract
Background & Aims Distinguishing malignant from benign primary solid liver lesions is highly important for treatment planning. However, diagnosis on radiological imaging is challenging. In this study, we developed a radiomics model based on magnetic resonance imaging (MRI) to distinguish the most common malignant and benign primary solid liver lesions, and externally validated the model in two centers.
Approach & Results Datasets were retrospectively collected from three tertiary referral centers (A, B and C) including data from affiliated hospitals sent for revision. Patients with malignant (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) and benign (hepatocellular adenoma and focal nodular hyperplasia) lesions were included. For each patient, only a T2-weighted MRI was included. A radiomics model was developed on dataset A using a combination of machine learning approaches, and internally evaluated on dataset A through cross-validation. Next, the model was externally validated on datasets B and C, and compared to scoring by two experienced abdominal radiologists on dataset C. In the resulting dataset, in total, 486 patients were included (A: 187, B: 98 and C: 201). Despite substantial MRI acquisition heterogeneity, the radiomics model developed on dataset A had a mean area under the receiver operating characteristic curve (AUC) of 0.78 in the internal validation on dataset A, and a similar AUC in the external validations (B: 0.74, C: 0.76). In dataset C, the two radiologists showed moderate agreement (Cohen’s κ: 0.61) and achieved AUCs of 0.86 and 0.82, respectively.
Conclusions Our radiomics model using T2-weighted MRI only can non-invasively distinguish malignant from benign primary solid liver lesions. External validation indicated that our model is generalizable despite substantial differences in the acquisition protocols.
Competing Interest Statement
Wiro Niessen is founder, scientific lead, and shareholder of Quantib BV. The other authors do not declare any conflicts of interest.
Funding Statement
Martijn Starmans acknowledges funding from the research program STRaTeGy (project number 14929-14930), which is (partly) financed by the Netherlands Organisation for Scientific Research (NWO). This work was partially carried out on the Dutch national e-infrastructure with the support of SURF Cooperative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for this study by the institutional review boards of Erasmus MC (Rotterdam, the Netherlands) (MEC-2017-1035), Maastricht UMC+ (Maastricht, the Netherlands) (METC 2018-0742), and Hopital Beaujon (Paris, France) (Nr. 2018-002) was obtained. Informed consent was waived due to the use of retrospective, anonymized data. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Mail: m.starmans{at}erasmusmc.nl; razvan.miclea{at}mumc.nl; valerie.vilgrain{at}aphp.fr; maxime.ronot{at}aphp.fr; yvonne.purcell{at}gmail.com; jef.verbeek{at}uzleuven.be; w.niessen{at}erasmusmc.nl; j.ijzermans{at}erasmusmc.nl; r.deman{at}erasmusmc.nl; m.doukas{at}erasmusmc.nl; s.klein{at}erasmusmc.nl; m.thomeer{at}erasmusmc.nl
Data availability statement: Imaging and clinical research data are not available at this time. Programming code is available on Zenodo at DOI https://doi.org/10.5281/zenodo.5175705.
Conflict of interest statement: Wiro Niessen is founder, scientific lead, and shareholder of Quantib BV. The other authors do not declare any conflicts of interest.
Financial support statement: No funding sources were involved in the study design, collection, analysis, and interpretation of data, writing the report, nor the decision to submit the article for publication.
Data Availability
Imaging and clinical research data are not available at this time. Programming code is available on Zenodo at DOI https://doi.org/10.5281/zenodo.5175705.
Abbreviations
- AUC
- area under the curve
- ADC
- apparent diffusion coefficient
- DSC
- Dice similarity coefficient
- EASL
- European association for the study of the liver
- FNH
- focal nodular hyperplasia
- HCA
- hepatocellular adenoma
- HCC
- hepatocellular carcinoma
- iCCA
- intrahepatic cholangiocarcinoma
- MRI
- magnetic resonance imaging
- ROC
- receiver operating characteristic
- WORC
- workflow for optimal radiomics classification
